Viyash Scientific Ltd (VIYASH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 213056,
    "name": "Viyash Scientifi",
    "stock_name": "Viyash Scientifi",
    "full_name": "Viyash Scientific Ltd",
    "name_url": "stocks-analysis/viyash-scientifi",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "201.60",
    "chg": -7.45,
    "chgp": "-3.56%",
    "dir": -1,
    "prev_price": "209.05",
    "mcapval": "8,798.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 512529,
    "symbol": "VIYASH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE807F01027",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "6.83 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/viyash-scientifi-213056-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MN",
      "url": "https://www.marketsmojo.com/mojopro/strategy/2",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/viyash-scientifi-213056-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Viyash Scientific Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-viyash-scientific-ltd-latest-results-good-or-bad-3824787",
        "imagepath": "",
        "date": "2026-02-06 19:21:21",
        "description": "Viyash Scientific Ltd's latest financial results for Q3 FY26 present a complex picture of operational performance and profitability challenges. The company reported a record revenue of ₹858.41 crores, reflecting a year-on-year growth of 10.90% and a slight sequential increase of 0.95%. This achievement highlights Viyash Scientific's ability to capture market share within the animal health pharmaceutical sector, despite a moderation in growth compared to previous quarters.\n\nHowever, the net profit for the same period was ₹38.44 crores, which represents a significant decline of 29.99% quarter-on-quarter and a 13.83% decrease year-on-year. This decline raises concerns regarding the sustainability of earnings, particularly as the profit margins have compressed. The PAT margin fell to 5.65%, down from 8.57% in the previous quarter, primarily due to increased tax expenses and higher depreciation charges.\n\nOn the ..."
      },
      {
        "title": "Viyash Scientific Ltd Reports Outstanding Quarterly Performance Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/viyash-scientific-ltd-reports-outstanding-quarterly-performance-amid-sector-challenges-3824262",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ViyashScientifi_fintrenddot_3824262.png",
        "date": "2026-02-06 11:00:08",
        "description": "Viyash Scientific Ltd has delivered an outstanding financial performance in the December 2025 quarter, marking a significant improvement in key metrics such as revenue growth, profitability, and operational efficiency. This robust quarter contrasts with the company’s previous trend and positions it favourably within the Pharmaceuticals & Biotechnology sector, despite a recent dip in share price and broader market volatility."
      },
      {
        "title": "Viyash Scientific Q3 FY26: Strong Revenue Growth Masks Profit Volatility and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/viyash-scientific-q3-fy26-strong-revenue-growth-masks-profit-volatility-and-valuation-concerns-3824248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ViyashScientifi_quaterlyResult_3824248.png",
        "date": "2026-02-06 09:32:58",
        "description": "Viyash Scientific Ltd. (formerly Sequent Scientific Ltd.), a leading integrated pharmaceutical company operating in animal health APIs and formulations, reported its Q3 FY26 results with consolidated net profit declining 29.99% quarter-on-quarter to ₹38.44 crores, despite revenue reaching an all-time high of ₹858.41 crores. The stock, trading at ₹200.85 with a market capitalisation of ₹9,121 crores, has declined 3.92% following the results announcement, reflecting investor concerns over profit volatility and stretched valuations at 206x P/E ratio."
      },
      {
        "title": "Are Viyash Scientific Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-viyash-scientific-ltd-latest-results-good-or-bad-3822854",
        "imagepath": "",
        "date": "2026-02-05 19:20:34",
        "description": "Viyash Scientific Ltd's latest financial results for the quarter ending September 2025 reflect a significant turnaround in performance compared to previous periods. The company reported consolidated net profit of ₹14.74 crores, showcasing a remarkable year-on-year growth of 464.75%, recovering from a loss-making phase in FY23-FY24. This performance indicates a strong recovery trajectory, particularly in profitability metrics.\n\nNet sales for the same quarter reached ₹423.99 crores, marking a year-on-year increase of 15.01%. However, it is noteworthy that this figure represents a slight sequential decline of 3.95% from the previous quarter. The operating margin also saw an improvement, reaching 13.13%, which is the highest level recorded in the past eight quarters, indicating enhanced operational efficiency.\n\nThe profit after tax margin expanded to 4.62%, up from 1.72% in the same quarter last year, further u..."
      },
      {
        "title": "Viyash Scientific Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/viyash-scientific-ltd-is-rated-hold-by-marketsmojo-3814063",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ViyashScientifi_mojoScore_3814063.png",
        "date": "2026-02-01 10:10:39",
        "description": "Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "When is the next results date for Sequent Scientific Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-sequent-scientific-ltd-3800738",
        "imagepath": "",
        "date": "2026-01-22 23:16:05",
        "description": "The next results date for Sequent Scientific Ltd is scheduled for February 5, 2026...."
      },
      {
        "title": "Sequent Scientific Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sequent-scientific-ltd-upgraded-to-hold-as-technicals-improve-amid-mixed-financial-signals-3795413",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SequentScientif_mojoScore_3795413.png",
        "date": "2026-01-20 08:07:43",
        "description": "Sequent Scientific Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and robust quarterly financial results. The upgrade, effective from 19 Jan 2026, is underpinned by a combination of enhanced technical trends, strong profit growth, rising promoter confidence, and a valuation that, while expensive, is supported by recent performance metrics."
      },
      {
        "title": "Sequent Scientific Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sequent-scientific-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3791441",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SequentScientif_mojoScore_3791441.png",
        "date": "2026-01-14 08:04:14",
        "description": "Sequent Scientific Ltd has seen its investment rating downgraded from Hold to Sell as of 13 January 2026, reflecting a complex interplay of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly results and rising promoter confidence."
      },
      {
        "title": "Sequent Scientific Ltd Faces Technical Momentum Shift Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sequent-scientific-ltd-faces-technical-momentum-shift-amid-mixed-market-signals-3791248",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SequentScientif_technicaldot_3791248.png",
        "date": "2026-01-14 08:00:28",
        "description": "Sequent Scientific Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish trend to a sideways movement. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s mixed technical signals across weekly and monthly charts suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 231,
    "sid": "213056",
    "stock_news_url": "https://www.marketsmojo.com/news/viyash-scientific-213056"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "06-Feb-2026",
      "details": "Investor Presentation Q3 FY26",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "06-Feb-2026",
      "details": "Audio Recording of Earnings call pertaining to the Unaudited Financial Results (Consolidated and Standalone) for the quarter and nine months December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "05-Feb-2026",
      "details": "Change in Management",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Viyash Scientific Ltd has declared <strong>25%</strong> dividend, ex-date: 08 Sep 21",
          "dt": "2021-09-08",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Viyash Scientific Ltd has announced <strong>2:10</strong> stock split, ex-date: 25 Feb 16",
          "dt": "2016-02-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Viyash Scientific Ltd latest results good or bad?

2026-02-06 19:21:21

Viyash Scientific Ltd's latest financial results for Q3 FY26 present a complex picture of operational performance and profitability challenges. The company reported a record revenue of ₹858.41 crores, reflecting a year-on-year growth of 10.90% and a slight sequential increase of 0.95%. This achievement highlights Viyash Scientific's ability to capture market share within the animal health pharmaceutical sector, despite a moderation in growth compared to previous quarters. However, the net profit for the same period was ₹38.44 crores, which represents a significant decline of 29.99% quarter-on-quarter and a 13.83% decrease year-on-year. This decline raises concerns regarding the sustainability of earnings, particularly as the profit margins have compressed. The PAT margin fell to 5.65%, down from 8.57% in the previous quarter, primarily due to increased tax expenses and higher depreciation charges. On the ...

Read full news article

Viyash Scientific Ltd Reports Outstanding Quarterly Performance Amid Sector Challenges

2026-02-06 11:00:08

Viyash Scientific Ltd has delivered an outstanding financial performance in the December 2025 quarter, marking a significant improvement in key metrics such as revenue growth, profitability, and operational efficiency. This robust quarter contrasts with the company’s previous trend and positions it favourably within the Pharmaceuticals & Biotechnology sector, despite a recent dip in share price and broader market volatility.

Read full news article

Viyash Scientific Q3 FY26: Strong Revenue Growth Masks Profit Volatility and Valuation Concerns

2026-02-06 09:32:58

Viyash Scientific Ltd. (formerly Sequent Scientific Ltd.), a leading integrated pharmaceutical company operating in animal health APIs and formulations, reported its Q3 FY26 results with consolidated net profit declining 29.99% quarter-on-quarter to ₹38.44 crores, despite revenue reaching an all-time high of ₹858.41 crores. The stock, trading at ₹200.85 with a market capitalisation of ₹9,121 crores, has declined 3.92% following the results announcement, reflecting investor concerns over profit volatility and stretched valuations at 206x P/E ratio.

Read full news article

Are Viyash Scientific Ltd latest results good or bad?

2026-02-05 19:20:34

Viyash Scientific Ltd's latest financial results for the quarter ending September 2025 reflect a significant turnaround in performance compared to previous periods. The company reported consolidated net profit of ₹14.74 crores, showcasing a remarkable year-on-year growth of 464.75%, recovering from a loss-making phase in FY23-FY24. This performance indicates a strong recovery trajectory, particularly in profitability metrics. Net sales for the same quarter reached ₹423.99 crores, marking a year-on-year increase of 15.01%. However, it is noteworthy that this figure represents a slight sequential decline of 3.95% from the previous quarter. The operating margin also saw an improvement, reaching 13.13%, which is the highest level recorded in the past eight quarters, indicating enhanced operational efficiency. The profit after tax margin expanded to 4.62%, up from 1.72% in the same quarter last year, further u...

Read full news article

Viyash Scientific Ltd is Rated Hold by MarketsMOJO

2026-02-01 10:10:39

Viyash Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

When is the next results date for Sequent Scientific Ltd?

2026-01-22 23:16:05

The next results date for Sequent Scientific Ltd is scheduled for February 5, 2026....

Read full news article

Sequent Scientific Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals

2026-01-20 08:07:43

Sequent Scientific Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and robust quarterly financial results. The upgrade, effective from 19 Jan 2026, is underpinned by a combination of enhanced technical trends, strong profit growth, rising promoter confidence, and a valuation that, while expensive, is supported by recent performance metrics.

Read full news article

Sequent Scientific Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-01-14 08:04:14

Sequent Scientific Ltd has seen its investment rating downgraded from Hold to Sell as of 13 January 2026, reflecting a complex interplay of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly results and rising promoter confidence.

Read full news article

Sequent Scientific Ltd Faces Technical Momentum Shift Amid Mixed Market Signals

2026-01-14 08:00:28

Sequent Scientific Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish trend to a sideways movement. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s mixed technical signals across weekly and monthly charts suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News